RedHill Biopharma (NASDAQ:RDHL) Now Covered by StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of RedHill Biopharma (NASDAQ:RDHL) in a research note issued to investors on Saturday. The brokerage set a “hold” rating on the biotechnology company’s stock.

RedHill Biopharma Stock Down 0.2 %

Shares of RDHL stock opened at $0.45 on Friday. The business has a 50-day moving average price of $0.50 and a two-hundred day moving average price of $0.75. RedHill Biopharma has a 12-month low of $0.26 and a 12-month high of $3.28.

Institutional Trading of RedHill Biopharma

An institutional investor recently bought a new position in RedHill Biopharma stock. Sabby Management LLC purchased a new position in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 635,006 shares of the biotechnology company’s stock, valued at approximately $324,000. RedHill Biopharma comprises approximately 0.2% of Sabby Management LLC’s portfolio, making the stock its 17th biggest holding. Sabby Management LLC owned approximately 5.74% of RedHill Biopharma as of its most recent filing with the SEC. Institutional investors own 7.20% of the company’s stock.

RedHill Biopharma Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.